快查:藥師家全台藥局藥品資訊

Interleukin | 合法藥品大搜索

Interleukin

由REMAP-CAPInvestigators著作·2021·被引用77次—MethodsWeevaluatedtocilizumabandsarilumab......Editor'sNote:ThisarticlewaspublishedonFebruary25,2021,atNEJM.org.

 Interleukin

由 REMAP-CAP Investigators 著作 · 2021 · 被引用 77 次 — Methods We evaluated tocilizumab and sarilumab... ... Editor's Note: This article was published on February 25, 2021, at NEJM.org.

閱讀更多

Tocilizumab nejm Tocilizumab nejm 類固醇的副作用多久會消失 盤尼西林用途 吃標靶藥還可生存多久 ertapenem副作用 Ertapenem seizure 鹽酸四環黴素用途 MEPENZOLATE BROMIDE 中文 中國化學製藥股份有限公司ptt
Tocilizumab in Patients Hospitalized with Covid | 合法藥品大搜索
由 C Salama 著作 · 2021 · 被引用 294 次 — Editor's Note: This article was published on December 17, 2020, at NEJM.org. Original Article. Tocilizumab in Patients Hospitalized with Covid-19 ... Read More
Tocilizumab in Hospitalized Patients with Severe Covid | 合法藥品大搜索
由 IO Rosas 著作 · 2021 · 被引用 109 次 — ... interleukin-6 levels. The use of tocilizumab, a monoclonal ... ... Editor's Note: This article was published on February 25, 2021, at NEJM.org. Read More
Efficacy of Tocilizumab in Patients Hospitalized with Covid | 合法藥品大搜索
由 JH Stone 著作 · 2020 · 被引用 547 次 — Editor's Note: This article was published on October 21, 2020, at NEJM.org. Original Article. Efficacy of Tocilizumab in Patients Hospitalized with ... Read More
Tocilizumab in Covid | 合法藥品大搜索
2021年4月22日 — Tocilizumab in Covid-19 Pneumonia ... Severe Covid-19 pneumonia occurs in approximately 15% of patients and is associated with high mortality. Read More
Tocilizumab in Covid | 合法藥品大搜索
2021年1月7日 — Stone et al. (Dec. 10 issue) report that tocilizumab had no significant effect on the risk of intubation or death in moderately ill patients ... Read More
Interleukin | 合法藥品大搜索
由 REMAP-CAP Investigators 著作 · 2021 · 被引用 77 次 — Methods We evaluated tocilizumab and sarilumab... ... Editor's Note: This article was published on February 25, 2021, at NEJM.org. Read More
Tocilizumab in Patients Hospitalized with Covid | 合法藥品大搜索
由 C Salama 著作 · 2021 · 被引用 294 次 — This article was published on December. 17, 2020, at NEJM.org. N Engl J Med 2021;384:20-30. DOI: 10.1056/NEJMoa2030340. Copyright © 2020 ... Read More
相關資訊整理

【安挺樂 靜脈點滴注射劑】1.類風濕性關節炎(RA) Actemra合併methotrexate (MTX)用於治療成年人中度至重度類風濕性關節炎，曾使用一種或一種以上之DMARD藥物治療或腫瘤壞死因子拮抗劑(TNF antagonist)治療而反應不佳或無法耐受的病人。在這些病人中，若病人對MTX無法耐受或不適合繼續投與MTX，可給予Actemra單獨治療。當Actemra 與MTX合併使用時，經X光量測，可減緩關節傷害惡化速度，此外，經HAQ-DI量表評估，可改善生理功能。2.類風濕性關節炎(RA)–未曾使用MTX治療的RA: Actemra合併methotrexate (MTX)適用於治療先前未曾使用MTX治療的重度、活動性、進行性類風濕性關節炎成人病人。在這些病人中，若病人對MTX無法耐受或不適合繼續投與MTX，可給予Actemra單獨治療。當Actemra與MTX合併使用時，經X光量測，可減緩關節傷害惡化速度。3.多關節性幼年型原發性關節炎(PJIA): Actemra與methotrexate (MTX)併用，適用於治療2歲(含)以上的活動性多關節性幼年型原發性關節炎，且對MTX治療反應不佳者。對於無法耐受或不適合繼續MTX治療的病人，可單獨使用Actemra。 4.全身性幼年型原發性關節炎(SJIA) :Actemra適用於治療2歲(含)以上的活動性全身性幼年型原發性關節炎病人，且對NSAID及類固醇治療反應不佳或無法耐受者。

藥品名稱:安挺樂靜脈點滴注射劑許可證字號:衛署菌疫輸字第000907號許可證種類:菌　疫適應症:1.類風濕性關節炎(RA)Actemra合...